Fluoxetine bioequivalence study: Quantification of fluoxetine and norfluoxetine by liquid chromatography coupled to mass spectrometry

Journal of Clinical Pharmacology

Volumn 39, Issue 10, 1999, Pages 1053-1061

  Moraes, M O ^a   Lerner, F E ^a   Corso, G ^a   Bezerra, F A F ^a   Moraes, M E A ^a   De Nucci, G ^a  

^a NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; NORFLUOXETINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; TABLET;

EID: 0033308481     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922011827     Document Type: Article

References (23)

1. The pharmacologic profile of fluoxetine
2. Clinical pharmacology and pharmacokinetics of fluoxetine: A review
3. The pharmacogenetics of the selective serotonin reuptake inhibitors
4. Clinical pharmacokinetics of fluoxetine
5. An analytical approximation to the distribution of Lilliefors's test statistic for normality
6. Pharmacokinetic analysis, bioavailability and operating guidelines
7. A distribution-free procedure for statistical analysis of bioequivalence studies
8. Quantification of fluoxetine and norfluoxetine serum levels by reversed-phase high-pressure liquid chromatography with ultraviolet detection
9. Pharmacogenetics in biological perspective
10. The extent and determinants of changes in CYP4502D6 and CYP1A2 activities with therapeutic doses of sertraline
11. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hidroxylase activity in human liver microsomes
12. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin
13. Evaluation of two assumptions: Single straight line and single normal distribution
14. Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism-hypothesis testing
15. Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism-histograms and probit plot
16. Comparative bioavailability of two sertraline tablet formulations in healthy human volunteers after a single dose administration
17. Fluconazole bioequivalence study: Quantification by tandem mass spectrometry
18. Genetic polymorphism of sparteine/debrisoquine oxidation: A reappraisal
19. Pharmacogenetics of antidepressants: Clinical aspects
20. Inhibition of CYP2D6 by selective serotonin reuptake inhibitors in vitro: Studies of phenytoin P-hydroxylation
21. Bioavailability and Bioequivalence Requirements
22. In vivo bioequivalence guidances
23. C(max)/AUC is a clearer measure than C(max) for absorption rates in investigations of bioequivalence